OGENライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:56):

Stats
本日の出来高	10 803.00
平均出来高	100 729
時価総額	4.69M
EPS	$0 ( 2024-04-17 )
次の収益日	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.230
ATR14	$0.0220 (2.14%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-31	Koski Robert C	Buy	0
2023-12-28	Redmond J Michael	Buy	75 000	Employee Option (Right to Buy)
2023-12-28	Redmond J Michael	Buy	0
2023-11-30	Telling Fred	Sell	3 500	Common Stock
2023-10-04	Gandolfo John P	Buy	5 102	Non-Employee Director Option (Right to Buy)

INSIDER POWER
44.74
Last 90 transactions
Buy: 9 608 650 \| Sell: 19 845 876

Oragenics Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Oragenics Inc 財務諸表

Annual	2023
収益:	$37 653.00
総利益:	$10 262.00 (27.25 %)
EPS:	$-9.18

FY	2023
収益:	$37 653.00
総利益:	$10 262.00 (27.25 %)
EPS:	$-9.18

FY	2022
収益:	$131 521
総利益:	$86 854.00 (66.04 %)
EPS:	$-7.05

FY	2021
収益:	$86 987.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00232

Financial Reports:

No articles found.

Oragenics Inc

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.